- Home
- CNP vs NTRA Comparison
CNP vs NTRA Comparison
Compare CNP & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNP
- NTRA
- Stock Information
- Founded
- CNP 1866
- NTRA 2003
- Country
- CNP United States
- NTRA United States
- Employees
- CNP N/A
- NTRA N/A
- Industry
- CNP Electric Utilities: Central
- NTRA Medical Specialities
- Sector
- CNP Utilities
- NTRA Health Care
- Exchange
- CNP Nasdaq
- NTRA Nasdaq
- Market Cap
- CNP 25.7B
- NTRA 27.0B
- IPO Year
- CNP N/A
- NTRA 2015
- Fundamental
- Price
- CNP $39.21
- NTRA $189.92
- Analyst Decision
- CNP Buy
- NTRA Strong Buy
- Analyst Count
- CNP 12
- NTRA 17
- Target Price
- CNP $41.29
- NTRA $196.24
- AVG Volume (30 Days)
- CNP 4.8M
- NTRA 1.2M
- Earning Date
- CNP 10-23-2025
- NTRA 11-06-2025
- Dividend Yield
- CNP 2.25%
- NTRA N/A
- EPS Growth
- CNP 5.29
- NTRA N/A
- EPS
- CNP 1.58
- NTRA N/A
- Revenue
- CNP $9,114,000,000.00
- NTRA $1,964,250,000.00
- Revenue This Year
- CNP $6.69
- NTRA $25.70
- Revenue Next Year
- CNP $5.90
- NTRA $15.42
- P/E Ratio
- CNP $24.75
- NTRA N/A
- Revenue Growth
- CNP 6.43
- NTRA 44.38
- 52 Week Low
- CNP $28.91
- NTRA $123.62
- 52 Week High
- CNP $40.50
- NTRA $203.23
- Technical
- Relative Strength Index (RSI)
- CNP 51.87
- NTRA 54.58
- Support Level
- CNP $37.81
- NTRA $193.29
- Resistance Level
- CNP $39.41
- NTRA $203.23
- Average True Range (ATR)
- CNP 0.60
- NTRA 7.30
- MACD
- CNP -0.08
- NTRA -0.33
- Stochastic Oscillator
- CNP 52.05
- NTRA 36.72
About CNP CenterPoint Energy Inc (Holding Co)
CenterPoint Energy owns a portfolio of businesses. Its regulated electric utilities provide transmission and distribution services to more than 2.5 million customers in the Houston area, southern Indiana, and west central Ohio. The company has natural gas distribution systems serving approximately 4 million customers.
About NTRA Natera Inc.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.